Merck launched its high-sensitivity detection platform, SMCxPRO™ technology in South Korea in March 2018. It was unveiled at the American Association for Cancer Research Annual Meeting in Washington, D.C.
The SMCxPRO™ platform allows researchers to detect and quantify low-abundance biomarkers that traditional methods cannot measure. The instrument features a high-sensitivity detection system, with speed and accuracy, in a compact design.
“Merck’s newest innovation, SMCxPRO™ technology, is part of a suite of tools for detecting and characterizing, accelerating drug discovery and improving overall lab productivity. Detection of low-abundance biomarkers allows for quantitation of a new class of novel targets. We are committed to empowering researchers by providing the technologies needed to accelerate advancements in healthcare.” said an official from Research Solutions, Life Science, Merck.
Along with the new SMCxPRO™ technology, Merck offers a wide range of solutions for biomarker discovery and novel target identification including its recently released Sanger CRISPR libraries that expand the company's suite of gene editing tools.
